Trial Profile

Korean Post-marketing Surveillance for Xeljanz 5 mg Film-coated Tablets and Xeljanz 1 mg/mL Oral Solution in Patients With Active pJIA and jPsA

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 22 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tofacitinib (Primary) ; Tofacitinib (Primary)
Indications Juvenile rheumatoid arthritis; Psoriatic arthritis
Focus Adverse reactions
Acronyms KRXeljanzJIA
Sponsors Pfizer

Most Recent Events

16 May 2024 Status changed to active, no longer recruiting.
19 Mar 2024 Planned initiation date changed from 31 Dec 2023 to 31 Dec 2024.
04 Sep 2023 Planned initiation date changed from 14 Aug 2023 to 31 Dec 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com